Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-10

Study Completion Date

2022-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative hospital stay.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multifactorial Evaluation of COVID-19 Respiratory Reliquates

NCT05607069

COVID-19 Respiratory Infection

UNKNOWN

The Role of Surgery in Patients With Coronavirus Disease - 19 (COVID-19) Related Thoracic Complications

NCT05204537

Surgical Complication COVID-19 Pneumothorax +4 more

COMPLETED

Post-COVID 19 Patients Undergoing Surgery

NCT04922931

Covid19

COMPLETED

The Impact of COVID-19 on Pulmonary Procedures

NCT05022446

COVID-19 Infection Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

RECRUITING

Pulmonary Surgery and Protective Mechanical Ventilation

NCT00805077

Lung Neoplasms

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted at the Lung Center of the Philippines. The study design is a retrospective case series implemented via chart review. Online and written patient records will be reviewed to determine the baseline patient characteristics and the preoperative outcomes. Patients who recovered from COVID-19 will be selected from those who underwent anatomic lung resection from June 1, 2020 to May 31, 2022. This study will be done in accordance with the Helsinky Declaration and Good Clinical Practice Guidelines, and will be subject for approval of the institutional Ethics and Technical Review Boards. Descriptive statistics will be used to describe patient characteristics and perioperative outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Lung Cancer Lung TB Hemoptysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients who recovered from COVID-19

patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)

anatomic lung resection

Intervention Type PROCEDURE

includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anatomic lung resection

includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* underwent anatomic lung resection
* previous COVID-19 infection documented by nasopharyngeal swab RT-PCR or GeneXpert
* with negative nasopharyngeal swab RT-PCR or GeneXpert prior to lung resection